Diana Mendus

859 total citations · 1 hit paper
15 papers, 587 citations indexed

About

Diana Mendus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Diana Mendus has authored 15 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Diana Mendus's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (7 papers) and CAR-T cell therapy research (3 papers). Diana Mendus is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (7 papers) and CAR-T cell therapy research (3 papers). Diana Mendus collaborates with scholars based in United States, Spain and France. Diana Mendus's co-authors include Tien Hoang, Manuel Cobo, Makoto Nishio, Rachel E. Sanborn, Silvia Novello, Zsuzsanna Szalai, Jerome H. Goldschmidt, Rodolfo Bordoni, Francesco Orlandi and S. Ball and has published in prestigious journals such as Genes & Development, PLoS ONE and Neuroscience.

In The Last Decade

Diana Mendus

15 papers receiving 582 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

2020 290 citations Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Diana Mendus

Since Specialization

Citations

This map shows the geographic impact of Diana Mendus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Mendus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Mendus more than expected).

Fields of papers citing papers by Diana Mendus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Mendus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Mendus. The network helps show where Diana Mendus may publish in the future.

Co-authorship network of co-authors of Diana Mendus

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Mendus. A scholar is included among the top collaborators of Diana Mendus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Mendus. Diana Mendus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) 2023 ·The Journal of Clinical Pharmacology ·Elena Garralda, Do Youn Oh, Antoîne Italiano, Philippe L. Bédard, Jean‐Pierre Delord, Emiliano Calvo, Patricia LoRusso, Zev A. Wainberg, Andrés Cervantes, Alejo Rodríguez‐Vida, Colby S. Shemesh, Rucha Sane, Diana Mendus, Hao Ding, Robert L. Hendricks, (unknown), Byoung Chul Cho, Tae Won Kim, Benjamin M. Wu	9
2	Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel 2021 ·Journal for ImmunoTherapy of Cancer ·David R. Gandara, Martin Reck, Denis Moro‐Sibilot, Julien Mazières, Shirish M. Gadgeel, Stefanie Morris, Andrés F. Cardona, Diana Mendus, Marcus Ballinger, Achim Rittmeyer, Solange Peters	14
3	LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer 2021 ·Annals of Oncology ·Zev A. Wainberg, Ignacio Matos, Jean‐Pierre Delord, Philippe A. Cassier, Marta Gil-Martín, (unknown), Patricia LoRusso, Rastilav Bahleda, Antoîne Italiano, Diana Mendus, Tien Hoang, (unknown), Xingqiao Wen, (unknown), Thao D. Pham, Namrata S. Patil, (unknown), Johanna C. Bendell, Andrés Cervantes, (unknown)	15
4	LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC 2021 ·Annals of Oncology ·B.C. Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Gregory J. Gerstner, Dongwook Kim, (unknown), Wu‐Chou Su, E.P. Huang, Namrata S. Patil, Mo Huang, (unknown), X. Wen, Diana Mendus, Tien Hoang, Robin Meng, Melissa L. Johnson	19
5	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells 2020 ·Molecular Oncology ·(unknown), (unknown), Diana Mendus, Ralf A. Hilger, Trudy G. Oliver, Kim L. Mercer, Björn-Oliver Gohlke, Kati Erdmann, Dieter Niederacher, Hans Neubauer, Paul Buderath, Pauline Wimberger, Jan Dominik Kuhlmann, Jürgen Thomale	7
6	Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. 2020 ·Journal of Thoracic Oncology ·Makoto Nishio, Fabrice Barlési, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski	7
7	375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC 2020 ·Annals of Oncology ·MAKI NISHIO, Fabrice Barlési, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray‐Longeras, Jerome H. Goldschmidt, Silvia Novello, F. Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, (unknown), Xingqiao Wen, Mark L. McCleland, Tien Hoang, S. Phan, Mark A. Socinski	9
8	Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial breakdown → 2020 ·Journal of Thoracic Oncology ·Makoto Nishio, Fabrice Barlési, Howard West, S. Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi, Rachel E. Sanborn, Zsuzsanna Szalai, (unknown), Diana Mendus, Lijia Wang, Xiaohui Wen, Mark L. McCleland, Tien Hoang, See Phan, Mark A. Socinski	290
9	OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC 2018 ·Journal of Thoracic Oncology ·Vassiliki A. Papadimitrakopoulou, Manuel Cobo, Rodolfo Bordoni, Pascale Dubray‐Longeras, Zsuzsanna Szalai, (unknown), Silvia Novello, Francesco Orlandi, S. Ball, Jerome H. Goldschmidt, Rachel E. Sanborn, Tien Hoang, Diana Mendus, Yu Deng, Marcin Kowanetz, (unknown), Wei Lin, Alan Sandler, Makoto Nishio	102
10	IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC) 2018 ·Annals of Oncology ·Fabrice Barlési, Makoto Nishio, Manuel Cobo, Nicola Steele, (unknown), (unknown), Rachel Dear, H. Bérard, Nir Peled, Lasika Seneviratne, Editta Baldini, Satoshi Watanabe, Keiko Goto, Diana Mendus, Hina Patel, Yu Deng, Marcin Kowanetz, Tien Hoang, Wei‐Hung Lin, Vassiliki A. Papadimitrakopoulou	44
11	Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC 2018 ·Annals of Oncology ·David R. Gandara, Martin Reck, S. Morris, Andrés F. Cardona, Diana Mendus, M. Ballinger, Achim Rittmeyer	21
12	Increased sensitivity to kindling in mice lacking TSP1 2015 ·Neuroscience ·Diana Mendus, (unknown), Mirna Mustapha, Brenda E. Porter	10
13	A Lack of Immune System Genes Causes Loss in High Frequency Hearing but Does Not Disrupt Cochlear Synapse Maturation in Mice 2014 ·PLoS ONE ·Melissa A. Calton, Dasom Lee, (unknown), Diana Mendus, (unknown), (unknown), Kenneth R. Johnson, Mirna Mustapha	11
14	Thrombospondins 1 and 2 are important for afferent synapse formation and function in the inner ear 2014 ·European Journal of Neuroscience ·Diana Mendus, (unknown), Nicolas Grillet, (unknown), (unknown), Ulrich Müller, Sherri M. Jones, Mirna Mustapha	22
15	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer 2010 ·Genes & Development ·Trudy G. Oliver, Kim L. Mercer, Leanne C. Sayles, James R. Burke, Diana Mendus, Katherine S. Lovejoy, (unknown), Aravind Subramanian, David Mu, Scott Powers, Denise Crowley, Roderick T. Bronson, Charles A. Whittaker, Arjun Bhutkar, Stephen J. Lippard, Todd R. Golub, Jüergen Thomale, Tyler Jacks, E. Alejandro Sweet‐Cordero	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact